X4 Pharmaceuticals, Inc (XFOR)
About X4 Pharmaceuticals, Inc
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $35.1M
- Net income
- -$79.2M
- Total assets
- $290.5M
- Market cap
- $361.2M
- Gross margin
- 68.8%
- Operating margin
- -1423.6%
- Net margin
- -1464.6%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $2.6M
- Cost of revenue
- $797.0K
- Gross profit
- $1.8M
- Operating expenses
- $38.2M
- Operating income
- -$36.4M
- Income tax
- $310.0K
- Net income
- -$37.5M
- EPS (basic)
- $-0.19
- EPS (diluted)
- $-0.19
Balance sheet
- Total assets
- $146.4M
- Current assets
- $112.2M
- Total liabilities
- $124.3M
- Current liabilities
- $32.9M
- Shareholders’ equity
- $22.1M
Cash flow
- Operating cash flow
- -$130.9M
- Investing cash flow
- $67.0M
- Financing cash flow
- $20.3M
- Net cash flow
- -$43.8M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $361.2M
- EPS (diluted)
- $-0.19
- Shares outstanding
- 93.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Nov 16, 2017
X4 Pharmaceuticals, Inc (XFOR) Stock Price
- Reported a net loss of $79.2M in FY2025.
- Revenue declined 15% from FY2020 to FY2024.
- Gross margin of 68.8%, net margin -1464.6%.
- Trading 18% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review X4 Pharmaceuticals, Inc.
Write a review
News about X4 Pharmaceuticals, Inc
News & sentiment via Polygon.io
X4 Pharmaceuticals, Inc: frequently asked questions
Is X4 Pharmaceuticals, Inc an American company?
X4 Pharmaceuticals, Inc is a US-based company headquartered in Boston, Massachusetts, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is X4 Pharmaceuticals, Inc headquartered?
X4 Pharmaceuticals, Inc is headquartered in Boston, Massachusetts, United States.
Is X4 Pharmaceuticals, Inc publicly traded?
Yes — X4 Pharmaceuticals, Inc is a publicly traded company. Its stock trades under the ticker symbol XFOR on the NASDAQ.
What does X4 Pharmaceuticals, Inc do?
X4 Pharmaceuticals, Inc is an American Pharmaceuticals company in the Health & Beauty sector.
